# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Ladenburg Thalmann analyst Aydin Huseynov downgrades Acrivon Therapeutics (NASDAQ:ACRV) from Buy to Neutral.
BMO Capital analyst Etzer Darout maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Outperform and raises the price target ...
JMP Securities analyst Silvan Tuerkcan maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Market Outperform and raises the ...
Piper Sandler analyst Joseph Catanzaro maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Overweight and raises the price t...
HC Wainwright & Co. analyst Emily Bodnar reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Buy and maintains $20 pric...
• Initial ACR-368 Phase 2b clinical data in patients with ovarian or endometrial cancers (n=26; 10 OncoSignature-positive and ...